NeuraLight launches the PARATROOPER trial to advance the understanding of Oculometric Biomarkers in Parkinsonian Disorders

The PARATROOPER (Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely) trial has officially launched — an observational clinical trial designed to explore how oculometric measures can help distinguish between parkinsonian syndromes and monitor disease progression over time.

Registered as NCT06597071 on ClinicalTrials.gov, the study is being conducted at the Instituto de Biomedicina de Sevilla (IBiS) under the leadership of Professor Pablo Mir, a leading movement disorders specialist in Spain.

PARATROOPER will enroll participants diagnosed with Parkinson’s disease (PD), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP), along with healthy control subjects, to better understand the oculometric patterns associated with each condition.

Over a 12-month period, the study will assess how eye movement patterns, captured using the NeuraLight platform, relate to established clinical and cognitive outcome measures.

By examining the relationship between oculometric biomarkers and disease severity, this study aims to advance understanding of eye movement dynamics in parkinsonian syndromes and contribute to the development of objective, quantifiable biomarkers that complement traditional neurological assessments.

The PARATROOPER study marks another step in NeuraLight’s mission to transform neurology and care through percise, AI-driven biomarkers.